Dexamethasone is the Preferred Steroid for Acute Tonsillitis
Use dexamethasone, not Kenalog (triamcinolone acetonide), for acute tonsillitis. Dexamethasone has strong guideline support and robust evidence for symptom relief in throat infections, while Kenalog lacks any evidence base for this indication and carries unnecessary risks.
Why Dexamethasone is Recommended
Guideline-Based Evidence
The American Academy of Otolaryngology-Head and Neck Surgery provides a strong recommendation for administering a single intraoperative dose of intravenous dexamethasone to children undergoing tonsillectomy, based on randomized controlled trials showing preponderance of benefit over harm 1, 2. While these guidelines specifically address surgical patients, the anti-inflammatory mechanism applies directly to acute tonsillitis management.
Clinical Benefits for Acute Tonsillitis
For patients with acute pharyngitis/tonsillitis, corticosteroids provide meaningful symptom relief:
- Pain resolution is 2.4 times more likely at 24 hours (RR 2.40,95% CI 1.29-4.47) and 1.5 times more likely at 48 hours when corticosteroids are added to standard care 3, 4
- Pain relief begins 4.8 hours earlier on average compared to placebo 3
- Complete pain resolution occurs 11.1 hours sooner 3
- Absolute pain reduction of 10.6% on visual analogue scales at 24 hours 3, 4
- Number needed to treat is 5 - meaning for every 5 patients treated, one additional patient will have complete pain resolution at 24 hours 4
Optimal Dosing
A single dose of oral or intramuscular dexamethasone 10 mg (or 0.5-0.6 mg/kg in children, maximum 10 mg) is the evidence-based approach 5. Lower doses (0.15-1.0 mg/kg) may be equally effective 1.
Why NOT Kenalog (Triamcinolone Acetonide)
Complete Absence of Evidence
There is zero published evidence supporting Kenalog use for acute tonsillitis or pharyngitis. The FDA label for Kenalog lists numerous indications, but acute tonsillitis and pharyngitis are conspicuously absent 6. The drug is approved for chronic conditions requiring prolonged anti-inflammatory effects, not acute infections.
Inappropriate Pharmacokinetics
Triamcinolone acetonide is a long-acting depot corticosteroid designed for sustained release over weeks. For acute tonsillitis requiring 24-48 hours of symptom control, this prolonged action is:
- Unnecessary for the clinical timeframe
- Potentially harmful due to extended immunosuppression
- Unable to be reversed if complications arise
Safety Concerns Specific to Kenalog
The FDA label explicitly warns about serious risks with Kenalog that are particularly problematic in infectious contexts 6:
- Immunosuppression leading to infection exacerbation - latent infections may activate or intercurrent infections may worsen
- Specific warnings about viral infections - chickenpox and measles can have serious or fatal courses in patients on corticosteroids
- Contraindication for intrathecal/epidural use with reports of serious neurologic events
- Benzyl alcohol content creates additional toxicity concerns
- Risk of Strongyloides hyperinfection in exposed patients
Practical Disadvantages
- Requires intramuscular injection (more invasive than oral dexamethasone)
- No dose-titration flexibility once administered
- Longer duration of action increases cumulative steroid exposure with recurrent episodes
Clinical Algorithm for Steroid Use in Acute Tonsillitis
Step 1: Confirm diagnosis
- Acute pharyngitis/tonsillitis with significant throat pain
- Exclude peritonsillar abscess, post-tonsillectomy pain, or infectious mononucleosis
Step 2: Screen for contraindications
- Active tuberculosis or strongyloides infection
- Recent chickenpox or measles exposure without immunity
- Diabetes with poor glucose control
- Patients already on chronic steroids
Step 3: Administer dexamethasone
- Adults: 10 mg oral or IM dexamethasone as single dose
- Children: 0.5-0.6 mg/kg oral or IM (maximum 10 mg)
- Give in addition to (not instead of) appropriate antibiotics if bacterial infection suspected
Step 4: Counsel patients
- Expect pain relief within 4-5 hours
- Continue prescribed antibiotics if given
- Return if symptoms worsen or new symptoms develop (fever, difficulty breathing, inability to swallow)
Important Caveats
Limited Pediatric Data
While the evidence supports corticosteroid use, only two of the included trials specifically studied children 4. The benefit appears consistent across age groups, but monitoring is prudent in pediatric populations.
Antibiotic Considerations
Most trials administered corticosteroids alongside antibiotics 4. The benefit of steroids appears additive to antibiotic therapy. Do not use steroids as a substitute for appropriate antibiotic treatment when bacterial infection is suspected (positive rapid strep test or Centor score ≥3).
Recurrent Episodes
The evidence base does not address cumulative steroid exposure in patients with frequent recurrent tonsillitis 3. For patients with multiple episodes, consider:
- Referral to ENT for tonsillectomy evaluation if meeting Paradise criteria
- Limiting steroid use to most severe episodes
- Documenting total steroid exposure over time
Adverse Events
Reported adverse events were rare and similar between steroid and placebo groups 3, 4. However, adverse event reporting was generally poor in the included studies. Single-dose therapy appears safe, but vigilance for complications (hyperglycemia, behavioral changes, immunosuppression) remains important.
The evidence unequivocally supports dexamethasone over Kenalog for acute tonsillitis - dexamethasone has proven efficacy, appropriate pharmacokinetics, and guideline support, while Kenalog has none of these and carries unnecessary risks for this indication.